U.S. markets close in 2 hours 34 minutes
  • S&P 500

    3,848.87
    +7.40 (+0.19%)
     
  • Dow 30

    30,926.14
    -70.84 (-0.23%)
     
  • Nasdaq

    13,608.16
    +65.10 (+0.48%)
     
  • Russell 2000

    2,153.60
    -15.16 (-0.70%)
     
  • Crude Oil

    52.51
    +0.24 (+0.46%)
     
  • Gold

    1,855.40
    -0.80 (-0.04%)
     
  • Silver

    25.50
    -0.05 (-0.20%)
     
  • EUR/USD

    1.2148
    -0.0027 (-0.22%)
     
  • 10-Yr Bond

    1.0470
    -0.0440 (-4.03%)
     
  • GBP/USD

    1.3672
    -0.0012 (-0.09%)
     
  • USD/JPY

    103.7750
    +0.0140 (+0.01%)
     
  • BTC-USD

    33,967.25
    +520.01 (+1.55%)
     
  • CMC Crypto 200

    684.06
    +7.16 (+1.06%)
     
  • FTSE 100

    6,638.85
    -56.22 (-0.84%)
     
  • Nikkei 225

    28,822.29
    +190.84 (+0.67%)
     

Bicycle Therapeutics to Present at the Canaccord Genuity 40th Annual Growth Conference

·1 min read

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in a fireside chat at the Canaccord Genuity 40th Annual Growth Conference on Wednesday, August 12, 2020 at 8:00 a.m. ET. The conference will be held in a virtual meeting format.

A live webcast of the fireside chat will be accessible in the Investors & Media section of Bicycle’s website at www.bicycletherapeutics.com. An archived replay of the webcast will be available for 90 days following the fireside chat date.

About Bicycle Therapeutics

Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles®, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development. Bicycle’s lead product candidate, BT1718, a Bicycle Toxin Conjugate (BTC) that targets MT1-MMP, is being investigated in an ongoing Phase I/IIa clinical trial in collaboration with the Centre for Drug Development of Cancer Research UK. Bicycle is also evaluating BT5528, a second-generation BTC targeting EphA2, in a Company-sponsored Phase I/II study. Bicycle is headquartered in Cambridge, UK with many key functions and members of its leadership team located in Lexington, MA. For more information, visit bicycletherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200805005085/en/

Contacts

Investor and Media Contact:
Bicycle Therapeutics
Maren Killackey
maren.killackey@bicycletx.com
+1-617-203-8300